The Value of 18FDG-PET/CT in Patients with Resectable Pancreatic Cancer: A Prospective Study
Context Whole-body 18fluor-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) has emerged as a promising diagnostic modality in different tumors. The role and the utility of 18FDG-PET/CT in resectable pancreatic cancer is debated. Objective To assess prospectively the value of 18FDG-PET/CT in addition to conventional imaging as a staging modality in candidates for resection of resectable pancreatic cancer. Methods Whole-body 18FDG-PET/CT was performed in 65 patients with pancreatic ductal adenocarcinoma who were judged resectable at high-resolution imaging. Neoadjuvant therapy was performed in the 20% of cases. Maximum standardized uptake value (SUVmax) was evaluated 60 and 250 minutes after FDG injection. Results Eight out of 65 (12%) patients were spared unwarranted resection since 18FDG-PET/CT detected synchronous advanced lung cancer (n=1) or metastatic disease (n=7). Median CA 19-9 was 53 kU/L for the entire cohort and 291 kU/L for seven patients with metastases (P=0.005). In other two patients 18FDG-PET/CT identified one colon carcinoma and a thoracic neurinoma. Thirteen out of 65 (20%) patients had low metabolic activity (SUVmax<3), and 46% of these patients had undergone neoadjuvant treatment (P=0.008). At laparotomy 3/57 (5%) patients did not undergo resection because of locally-advanced (n=1) or metastatic disease (n=2). Fifty-four patients underwent pancreatic resections associated with 11 (20%) vascular resections and one left colectomy. N1 rate was 76%, with a median of 33 resected nodes. In 8/54 (15%) patients 18FDG-PET/CT identified metastatic lymph nodes that required an extension of lymphadenectomy. Sensitivity and specificity of 18FDG-PET/CT for the detection of metastatic disease were 80% and 100%, respectively. Conclusion 18FDG-PET/CT findings resulted in changes of therapeutic management/operative procedures in one third of patients. 18FDG-PET/CT improves staging of patients with resectable pancreatic cancer. Neoadjuvant treatment is significantly associated with low metabolic activity limiting the value of 18FDG-PET/CT in this setting.
Copyright (c) 2014 Stefano Crippa, Matteo Salgarello, Silvia Laiti, Stefano Partelli, Giuliano Barugola, Paola Castelli, Giuseppe Zamboni, Massimo Falconi
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.